Form 8.3 - ASSURA PLC | 31-Mar-2025 | 15:27 | RNS |
Form 8.3 - Primary Health Properties PLC | 31-Mar-2025 | 15:25 | RNS |
Form 8.3 - Primary Health Properties Plc | 31-Mar-2025 | 15:21 | GlobeNewswire NA |
Form 8.3 - Primary Health Properties plc | 31-Mar-2025 | 15:20 | RNS |
Form 8.3 - Primary Health Properties PLC | 31-Mar-2025 | 14:02 | RNS |
Form 8.3 - Primary Health Properties plc | 31-Mar-2025 | 13:15 | RNS |
Form 8.3 - Primary Health Properties plc | 31-Mar-2025 | 13:03 | RNS |
Form 8.5 (EPT/RI)Primary Health Properties Plc | 31-Mar-2025 | 12:00 | RNS |
Form 8.3 - Primary Health Properties plc | 31-Mar-2025 | 11:31 | RNS |
Form 8.5(EPT/NON-RI)-Primary Health Properties plc | 31-Mar-2025 | 11:11 | RNS |
Form 8.5(EPT/NON-RI)-Primary Health Properties plc | 31-Mar-2025 | 11:09 | RNS |
Form 8.5 (EPT/RI)-Primary Health Properties plc | 31-Mar-2025 | 11:07 | RNS |
Form 8.3 - Primary Health Properties PLC | 31-Mar-2025 | 10:45 | RNS |
Form 8.5- Primary Health Properties Plc | 31-Mar-2025 | 10:39 | RNS |
Dimensional Fund Advisors Ltd. : Form 8.3 - PRIM... | 31-Mar-2025 | 09:40 | GlobeNewswire NA |
Currency | UK Pounds |
Share Price | 94.45p |
Change Today | -0.35p |
% Change | -0.37 % |
52 Week High | 102.30p |
52 Week Low | 86.15p |
Volume | 2,035,707 |
Shares Issued | 1,336.49m |
Market Cap | £1,262.32m |
RiskGrade | 84 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 3 |
Buy | 1 |
Neutral | 3 |
Sell | 0 |
Strong Sell | 0 |
Total | 7 |
Latest | Previous | |
---|---|---|
Q2 | Q1 | |
Ex-Div | 27-Mar-25 | 09-Jan-25 |
Paid | 09-May-25 | 21-Feb-25 |
Amount | 1.77p | 1.77p |
Time | Volume / Share Price |
15:17 | 815 @ 94.40p |
15:17 | 940 @ 94.45p |
15:17 | 1,131 @ 94.45p |
15:17 | 443 @ 94.45p |
15:17 | 1,832 @ 94.45p |
CFO | Richard Howell |
CEO | Mark Davies |
You are here: research